Skip to main content
Premium Trial:

Request an Annual Quote

Amersham and Two Biotechs to Develop Media for Large-Scale Protein Separation

NEW YORK, March 6 - Amersham Biosciences and biotech firms Dyax and Affibody plan to co-develop affinity-based chromatographic media for large-scale protein separation and purification, Amersham said on Wednesday.

Terms of the agreement call for Dyax to give Amersham non-exclusive rights to its phage-display affinity-ligand discovery process, which designed to find ligands that may be used in chromatography separation. Amersham said it intends to use the technology for "specific customer needs and to develop more broadly applicable products for the protein separations field."

Meanwhile, Amersham and Affibody will develop a class of small affinity proteins, which the companies call Affibodies, designed to bind to desired protein targets.

Financial terms of the agreements were not disclosed.

"Through these deals, Amersham Biosciences will develop and commercialize new media products with high affinity, selectivity and capacity," Peter Ehrenheim, vice president of protein separations at Amersham Biosciences, said in a statement.

 

Dyax is based in Cambridge, Mass. Affinity has headquarters in Stockholm, Sweden.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.